Literature DB >> 35082480

Running the Risk: Exercise and Arrhythmogenic Cardiomyopathy.

Lauren Eberly1,2,3, Lohit Garg1, Mahesh Vidula1, Nosheen Reza1, Sheela Krishnan1.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to summarize what is known about the relationship between exercise and arrhythmogenic right ventricular cardiomyopathy (ARVC) with regard to disease onset, diagnosis, progression, and clinical severity. This relationship forms the basis of the management recommendations for restricting physical activity in individuals with and at risk for ARVC. RECENT
FINDINGS: While ARVC can be challenging to diagnose, there are several diagnostic testing and imaging modalities that may help distinguish athletic heart remodeling from ARVC. There is an increased risk of adverse clinical outcomes in ARVC from endurance and competitive sports participation, including a dose-dependent relationship between exercise intensity and risk of disease penetrance and progression.
SUMMARY: High-intensity exercise can lead to earlier disease onset, increased penetrance, and clinical progression among individuals with and at risk for ARVC. Both amount and intensity of exercise are correlated with adverse outcomes, including ventricular arrhythmias and worsening biventricular function. All individuals with and at risk for ARVC should undergo detailed clinical phenotyping and risk stratification to reduce the risk of such outcomes, including sudden cardiac death. Consensus guidelines recommend against participation in competitive or high-intensity and endurance exercise for individuals with and at risk for ARVC.

Entities:  

Keywords:  Arrhythmia; Arrhythmogenic cardiomyopathy; Arrhythmogenic right ventricular cardiomyopathy; Exercise; Risk stratification; Sudden death

Year:  2021        PMID: 35082480      PMCID: PMC8785909          DOI: 10.1007/s11936-021-00943-0

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  60 in total

1.  Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.

Authors:  Aditya Bhonsale; Cynthia A James; Crystal Tichnell; Brittney Murray; Dmitri Gagarin; Binu Philips; Darshan Dalal; Ryan Tedford; Stuart D Russell; Theodore Abraham; Harikrishna Tandri; Daniel P Judge; Hugh Calkins
Journal:  J Am Coll Cardiol       Date:  2011-09-27       Impact factor: 24.094

Review 2.  Task Force 8: classification of sports.

Authors:  Jere H Mitchell; William Haskell; Peter Snell; Steven P Van Camp
Journal:  J Am Coll Cardiol       Date:  2005-04-19       Impact factor: 24.094

3.  Managing Secondary Genomic Findings Associated With Arrhythmogenic Right Ventricular Cardiomyopathy: Case Studies and Proposal for Clinical Surveillance.

Authors:  Christopher M Haggerty; Brittney Murray; Crystal Tichnell; Daniel P Judge; Harikrishna Tandri; Marci Schwartz; Amy C Sturm; Martin E Matsumura; Michael F Murray; Hugh Calkins; Brandon K Fornwalt; Cynthia A James
Journal:  Circ Genom Precis Med       Date:  2018-07

4.  Right ventricular cardiomyopathy and sudden death in young people.

Authors:  G Thiene; A Nava; D Corrado; L Rossi; N Pennelli
Journal:  N Engl J Med       Date:  1988-01-21       Impact factor: 91.245

5.  Predictors of appropriate implantable defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia.

Authors:  Jonathan P Piccini; Darshan Dalal; Ariel Roguin; Chandra Bomma; Alan Cheng; Kalpana Prakasa; Jun Dong; Crystal Tichnell; Cynthia James; Stuart Russell; Jane Crosson; Ronald D Berger; Joseph E Marine; Gordon Tomaselli; Hugh Calkins
Journal:  Heart Rhythm       Date:  2005-11       Impact factor: 6.343

6.  Long-term follow-up in patients with arrhythmogenic right ventricular disease.

Authors:  F I Marcus; G H Fontaine; R Frank; J J Gallagher; M J Reiter
Journal:  Eur Heart J       Date:  1989-09       Impact factor: 29.983

7.  High prevalence of right ventricular involvement in endurance athletes with ventricular arrhythmias. Role of an electrophysiologic study in risk stratification.

Authors:  Hein Heidbüchel; Jan Hoogsteen; Robert Fagard; L Vanhees; Hugo Ector; Rik Willems; Johan Van Lierde
Journal:  Eur Heart J       Date:  2003-08       Impact factor: 29.983

8.  Right ventricular dysplasia: a report of 24 adult cases.

Authors:  F I Marcus; G H Fontaine; G Guiraudon; R Frank; J L Laurenceau; C Malergue; Y Grosgogeat
Journal:  Circulation       Date:  1982-02       Impact factor: 29.690

9.  Prognostic value of endocardial voltage mapping in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.

Authors:  Federico Migliore; Alessandro Zorzi; Maria Silvano; Michela Bevilacqua; Loira Leoni; Martina Perazzolo Marra; Mohamed Elmaghawry; Luca Brugnaro; Carlo Dal Lin; Barbara Bauce; Ilaria Rigato; Giuseppe Tarantini; Cristina Basso; Gianfranco Buja; Gaetano Thiene; Sabino Iliceto; Domenico Corrado
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-02-07

10.  Impact of Exercise Restriction on Arrhythmic Risk Among Patients With Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Weijia Wang; Gabriela Orgeron; Crystal Tichnell; Brittney Murray; Jane Crosson; Oliver Monfredi; Julia Cadrin-Tourigny; Harikrishna Tandri; Hugh Calkins; Cynthia A James
Journal:  J Am Heart Assoc       Date:  2018-06-16       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.